Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2022-03-02 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on movements in Securities for the month ended 28 February 2022
Regulatory Filings Classification · 95% confidence The document is a monthly return detailing movements in securities for an equity issuer listed on the Hong Kong Stock Exchange. It includes information on authorized and issued shares, share options, and confirmations related to securities issuance. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital and share movements for the month ended 28 February 2022. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. It is a regulatory filing reporting share capital movements and confirmations, fitting the category of Regulatory Filings (RNS).
2022-03-02 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from Ascletis Pharma Inc. regarding a scheduled board meeting to consider and approve the annual results for the year ended December 31, 2021, and the recommendation of a final dividend. It does not contain the actual annual results or financial data but merely notifies the market of the upcoming board meeting where these matters will be discussed. The document length is only 1334 characters, which is quite short and consistent with an announcement rather than a full report. According to the 'MENU VS MEAL' rule, this is an announcement about a report (annual results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit into other specific categories.
2022-03-02 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN EIGHT ADDITIONAL EUROPEAN COUNTRIES
Regulatory Filings Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding the submission of marketing authorization applications for ritonavir in multiple European countries. It is labeled as an "ANNOUNCEMENT INSIDE INFORMATION" and references compliance with the Listing Rules of the Hong Kong Stock Exchange and the Securities and Futures Ordinance. The content focuses on regulatory submissions and business updates related to product marketing approvals, not on financial results, management changes, or shareholder votes. The document is relatively short (3922 characters) and serves as a regulatory announcement rather than a detailed report or financial filing. It does not contain financial statements or detailed financial data, nor is it a report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-03-01 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 95% confidence The document is titled 'POSITIVE PROFIT ALERT' and is an announcement by Ascletis Pharma Inc. regarding preliminary unaudited financial results for the year ended December 31, 2021. It provides estimated financial performance figures such as gross profit, revenue, and net loss, but explicitly states that the final annual results are still being finalized and will be published later. The document is relatively short (3782 characters) and serves as a preliminary profit alert rather than a full annual report or earnings release. It does not contain detailed financial statements or comprehensive analysis, but rather a summary of expected results. This type of document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. FY 2021
2022-02-27 English
VOLUNTARY ANNOUNCEMENT - SHANGHAI PUBLIC HEALTH CLINICAL CENTER INITIATED FUNCTIONAL CURE STUDY OF ANTI-PD-L1 ANTIBODY ASC22 (ENVAFOLIMAB) IN COMBINATION WITH CHIDAMIDE IN HIV-INFECTED PATIENTS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the initiation of a clinical study involving a drug candidate. It is not a financial report, earnings release, or regulatory filing related to financial performance or corporate governance. The document is relatively short (2923 characters) and serves as an announcement of a clinical trial initiation rather than a detailed report or presentation. It does not contain financial data, management discussion, or voting results. It is not a report publication announcement since it does not mention the release or availability of a report. The content is primarily an announcement of a clinical study initiation, which fits best under the category of a general regulatory announcement or miscellaneous filing that does not fit other categories.
2022-02-14 English
ANNOUNCEMENT - INSIDE INFORMATION - ASCLETIS ANNOUNCES SUBMISSION OF MARKETING AUTHORIZATION APPLICATIONS FOR RITONAVIR IN MULTIPLE EUROPEAN COUNTRIES
Regulatory Filings Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding the submission of marketing authorization applications for ritonavir in multiple European countries. It is labeled as an "ANNOUNCEMENT INSIDE INFORMATION" and references compliance with the Listing Rules of the Hong Kong Stock Exchange and the Securities and Futures Ordinance. The content focuses on regulatory submissions and commercial supply discussions, not on financial results, management changes, or shareholder votes. The document length is 3818 characters, which is relatively short and typical for an announcement rather than a full report. There is no detailed financial data, no meeting materials, no voting results, no executive compensation details, and no legal proceeding updates. The document is clearly an official regulatory announcement about a significant corporate event (submission of marketing authorization applications), which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit more specific categories like Capital/Financing Update or Legal Proceedings Report.
2022-02-13 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.